Pro Tip: Learn how to use HBI Alerts to follow your favorite topics

Austria

 

German insurer Barmer will reimburse Austrian femtech Hello Inside

Barmer, Germany’s second largest non-profit statutory health insurer with around 8.7 million members, has partnered with Austrian femtech company Hello Inside to offer its metabolic health programme as a reimbursed prevention service. Mario Aichlseder, Hello Inside’s co-founder, explained to us how this an important step in demonstrating that the company’s offering is a healthcare product, rather than a wellness product.

HBI 2026: Why now is the time to invest in DACH

Across Europe, the DACH region stands out for its scale, stability, and potential for consolidation.  At HBI 2026, a panel of senior investors and operators highlighted why the region is increasingly seen as an attractive and underappreciated market for healthcare consolidation.

Fremman buys Stingray to merge with Amethyst

Two of Europe’s three largest private oncology groups are being merged into a single entity, creating continental Europe’s largest oncology player. Private equity firm Fremman Capital has acquired Stingray, an oncology group with a presence in France and Germany, to merge it with its portfolio company Amethyst, a major pan-European radiotherapy group which already has a presence in seven European countries.

Interview: Stéphane Carré, Amethyst Radiotherapy Group

In this interview Stéphane Carré, CEO of pan-European radiotherapy provider Amethyst Radiotherapy, explains how his company is aiming to increase access to state of the art radiotherapy services, and provide a holistic care journey geared towards making the patient feel as comfortable as possible. Stéphane Carré will be sharing more about his business model at HBI 2025, in Paris, March 24-26, 2025.

Interview: Dr. Volker Wendel, Sanoptis

Dr. Volker Wendel founded Sanoptis in 2018 in Switzerland with Carsten Horn. Six years later, the group has grown to more than 400 locations across six European countries. The group was initially backed by PE firm Telemos Capital, who then sold it to Belgian holding company Group Bruxelles Lambert (in 2022). Wendel explains to us how the group is able to add value to ophthalmologists who join the network and shares which areas the group will be focusing on in the coming years.

PAI Partners to acquire Vamed rehab clinics

French PE firm PAI Partners will become the new owner of Fresenius Vamed’s rehab business. Vamed is currently a subsidiary of German health care conglomerate Fresenius, who will continue to hold a minority stake.

EU’s AI Act gets the greenlight from the European Commission

Despite opposition, the AI Act seems to be ploughing ahead right on schedule. This week, two key groups of lawmakers - the European Commission's civil liberties (LIBE) and internal market (IMCO) committees - gave their overwhelming support for the new law, which should come into force this summer.

EU states approve AI Act

In December, European policymakers gathered in Brussels to hash out the first framework for AI regulation. Despite threats to derail it, all 27 EU member states have now given it a collective thumbs up - but concerns around overregulation, bureaucracy, and the stifling of innovation remain. 

New entrants could disrupt “tough” fertility market

The cost-of-living crisis is having a huge impact on fertility patients, making the sector ripe for disruption. A fertility expert tells HBI cunning new entrants will be the winners while established PE could well be the losers.

New AI act could stifle EU innovation – but benefit the UK

After 38 hours of deliberation, a long-awaited deal has finally been reached in Brussels. HBI speaks to three market experts to understand what the AI Act - the comprehensive European framework for AI innovation and regulation - could mean for the future of healthcare in Europe.

Find Us